Incyte Corp. buy stratec
Start price
19.02.20
/
50%
€75.44
Target price
04.11.21
€100.00
Performance (%)
-22.53%
End price
05.11.21
€58.44
Summary
This prediction ended on 05.11.21 with a price of €58.44. The price of Incyte Corp. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -22.53%. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Incyte Corp. | 2.237% | 2.237% | 25.726% | 7.454% |
| iShares Core DAX® | -1.212% | 1.925% | 17.589% | 68.786% |
| iShares Nasdaq 100 | -4.714% | -1.810% | 0.450% | 100.066% |
| iShares Nikkei 225® | -2.976% | -2.660% | 10.156% | 43.024% |
| iShares S&P 500 | -2.744% | -0.448% | 0.320% | 63.222% |
Comments by stratec for this prediction
In the thread Incyte Corp. diskutieren
Incyte (NASDAQ:INCY) perks up 2% premarket on light volume on the heels of its announcement of positive results from a second Phase 3 clinical trial, TRuE-AD1, evaluating ruxolitinib cream 0.75% or 1.5% in patients at least 12 years old with mild-to-moderate atopic dermatitis (AD). The study met the primary endpoint of a statistically significant proportion of treated patients achieving clear or almost clear skin at week 8 compared to vehicle (placebo). A sister Phase 3, TRuE-AD2, was also successful. Marketing applications should be the next step.
Kursziel geändert auf 100,0
In the thread Trading Incyte Corp.
Die von stratec gewählte maximale Laufzeit wurde überschritten